AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1142	72509-76-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: felodipine (RS)-Felodipine (+/-)-Felodipine flodil dl-Felodipine	A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. Molecular weight: 384.25 Formula: C18H19Cl2NO4 CLOGP: 5.30 LIPINSKI: 1 HAC: 5 HDO: 1 TPSA: 64.63 ALOGS: -4.73 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

felodipine
(RS)-Felodipine
(+/-)-Felodipine
flodil
dl-Felodipine

A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.

Molecular weight: 384.25
Formula: C18H19Cl2NO4
CLOGP: 5.30
LIPINSKI: 1
HAC: 5
HDO: 1
TPSA: 64.63
ALOGS: -4.73
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.25 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.87 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	4.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK4,PDPK1,PIK3CB,PIK3CG,PRKDC,TEK	20
kinase-selectivity-class	AXL,BRAF,GRK2,PDK4,PIK3CB,PIK3CD	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
July 25, 1991	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	357.95	17.92	93	19272	3353	90605729
Palmoplantar keratoderma	356.34	17.92	93	19272	3414	90605668
Pruritus genital	332.18	17.92	93	19272	4465	90604617
Sleep terror	320.40	17.92	90	19275	4374	90604708
Carotid artery occlusion	310.33	17.92	95	19270	6247	90602835
Atrial tachycardia	294.26	17.92	90	19275	5900	90603182
Tension headache	282.32	17.92	92	19273	7417	90601665
Anosmia	257.87	17.92	92	19273	9756	90599326
Vasculitis	247.95	17.92	113	19252	22580	90586502
Immunisation	236.02	17.92	61	19304	2152	90606930
Muscle twitching	234.83	17.92	111	19254	24091	90584991
Facial pain	228.27	17.92	91	19274	13091	90595991
Pain of skin	220.69	17.92	94	19271	15988	90593094
Subarachnoid haemorrhage	220.65	17.92	97	19268	17807	90591275
Tinnitus	215.81	17.92	127	19238	42975	90566107
Ventricular tachycardia	196.71	17.92	99	19266	24609	90584473
Lip swelling	191.28	17.92	113	19252	38497	90570585
Hallucination	189.06	17.92	137	19228	65822	90543260
Blindness	175.73	17.92	94	19271	26474	90582608
Eye pruritus	173.40	17.92	96	19269	28931	90580151
Diplopia	166.15	17.92	93	19272	28621	90580461
Angioedema	164.07	17.92	125	19240	64751	90544331
Transient ischaemic attack	157.39	17.92	104	19261	43072	90566010
Disturbance in attention	146.82	17.92	103	19262	47006	90562076
Palpitations	116.86	17.92	145	19220	136583	90472499
Rash papular	115.23	17.92	65	19300	20290	90588792
Hyponatraemia	100.54	17.92	133	19232	133405	90475677
Cognitive disorder	98.30	17.92	96	19269	69311	90539771
Myocardial infarction	98.02	17.92	117	19248	105855	90503227
Dehydration	96.29	17.92	159	19206	194288	90414794
Intentional product misuse	87.96	17.92	102	19263	89502	90519580
Tachycardia	84.95	17.92	134	19231	157539	90451543
Blood creatine increased	83.40	17.92	37	19328	6930	90602152
Blood glucose increased	81.32	17.92	101	19264	95145	90513937
Hyperhidrosis	80.67	17.92	121	19244	136184	90472898
Dry skin	79.40	17.92	96	19269	87977	90521105
Heart rate increased	76.69	17.92	107	19258	112795	90496287
Drug ineffective	73.00	17.92	115	19250	1384183	89224899
Visual impairment	69.23	17.92	111	19254	132254	90476828
Infusion related reaction	67.05	17.92	6	19359	416774	90192308
COVID-19	66.61	17.92	125	19240	168718	90440364
Amnesia	66.59	17.92	98	19267	108407	90500675
Dizziness	65.53	17.92	274	19091	589010	90020072
Arthropathy	62.51	17.92	4	19361	366238	90242844
Hypopnoea	61.10	17.92	26	19339	4405	90604677
Drug intolerance	58.91	17.92	12	19353	447579	90161503
Maternal exposure during pregnancy	58.40	17.92	5	19360	360058	90249024
Catarrh	57.30	17.92	19	19346	1615	90607467
Migraine	53.95	17.92	123	19242	190269	90418813
Burns second degree	53.72	17.92	19	19346	1961	90607121
Drug interaction	52.87	17.92	154	19211	276299	90332783
Feeling abnormal	51.83	17.92	112	19253	167123	90441959
Steroid dependence	51.19	17.92	19	19346	2250	90606832
Contraindicated product administered	50.43	17.92	5	19360	320134	90288948
Medication error	48.42	17.92	74	19291	84578	90524504
Wound	47.03	17.92	5	19360	302975	90306107
Accidental overdose	45.52	17.92	42	19323	28231	90580851
Hepatic enzyme increased	44.78	17.92	11	19354	360725	90248357
Bradycardia	44.76	17.92	71	19294	83776	90525306
Therapeutic product effect decreased	44.60	17.92	4	19361	277567	90331515
Swollen tongue	44.54	17.92	52	19313	45904	90563178
Back pain	43.72	17.92	158	19207	317017	90292065
Infection	43.12	17.92	12	19353	362082	90247000
Nightmare	42.41	17.92	36	19329	21689	90587393
Discomfort	39.01	17.92	6	19359	274329	90334753
Dopamine transporter scintigraphy abnormal	38.96	17.92	8	19357	98	90608984
Treatment failure	38.24	17.92	9	19356	303919	90305163
Memory impairment	37.79	17.92	110	19255	197134	90411948
Hyperkalaemia	37.44	17.92	57	19308	64907	90544175
Swelling	36.78	17.92	22	19343	419036	90190046
Muscular weakness	35.59	17.92	111	19254	206555	90402527
Acute kidney injury	35.51	17.92	149	19216	320238	90288844
Serotonin syndrome	33.64	17.92	41	19324	37846	90571236
Rectal haemorrhage	32.27	17.92	61	19304	82683	90526399
Chest pain	31.11	17.92	143	19222	319502	90289580
Therapeutic product effect incomplete	30.59	17.92	3	19362	193893	90415189
Rheumatoid arthritis	30.48	17.92	20	19345	362594	90246488
Tubulointerstitial nephritis	30.28	17.92	32	19333	25311	90583771
Spider naevus	29.51	17.92	7	19358	172	90608910
Asthma	28.86	17.92	8	19357	242152	90366930
Type 2 diabetes mellitus	27.66	17.92	5	19360	203239	90405843
Sinusitis	27.40	17.92	20	19345	343068	90266014
Nasopharyngitis	27.34	17.92	28	19337	407076	90202006
Cardiac murmur	27.31	17.92	26	19339	18168	90590914
Anxiety	26.82	17.92	134	19231	309638	90299444
Musculoskeletal stiffness	26.81	17.92	15	19350	296517	90312565
Polyuria	26.80	17.92	20	19345	10020	90599062
Weight increased	26.67	17.92	30	19335	417897	90191185
Hyperreflexia	26.60	17.92	17	19348	6640	90602442
Parosmia	25.67	17.92	17	19348	7052	90602030
Hyperlactacidaemia	25.57	17.92	14	19351	4122	90604960
IIIrd nerve paresis	25.47	17.92	6	19359	143	90608939
Gingival pain	25.26	17.92	19	19346	9633	90599449
Ultrasound kidney abnormal	25.10	17.92	5	19360	52	90609030
Neonatal anuria	25.10	17.92	5	19360	52	90609030
Exposure during pregnancy	24.70	17.92	10	19355	238400	90370682
Psoriatic arthropathy	24.62	17.92	9	19356	228326	90380756
Injection site pain	24.23	17.92	4	19361	173695	90435387
Ill-defined disorder	24.20	17.92	5	19360	184886	90424196
Drug hypersensitivity	23.80	17.92	39	19326	463570	90145512
Retinal detachment	23.80	17.92	16	19349	6806	90602276
Clonus	23.77	17.92	15	19350	5735	90603347
Skin oedema	23.62	17.92	9	19356	1145	90607937
Malaise	23.47	17.92	209	19156	585777	90023305
Sinus bradycardia	23.15	17.92	23	19342	16929	90592153
Nodal rhythm	22.87	17.92	10	19355	1808	90607274
Blood cholesterol increased	22.76	17.92	8	19357	208004	90401078
Intentional overdose	22.64	17.92	57	19308	93777	90515305
Distributive shock	22.30	17.92	12	19353	3412	90605670
Iodine allergy	22.14	17.92	8	19357	878	90608204
Lethargy	21.53	17.92	44	19321	63095	90545987
Gingival hypertrophy	21.05	17.92	10	19355	2190	90606892
Capillary disorder	21.03	17.92	5	19360	124	90608958
Hypersensitivity	20.86	17.92	41	19324	454636	90154446
Stomatitis	20.68	17.92	17	19348	274681	90334401
Confusional state	20.50	17.92	147	19218	386058	90223024
Syncope	19.89	17.92	68	19297	132595	90476487
Rhinitis	19.62	17.92	19	19346	13553	90595529
Death	19.41	17.92	43	19322	456508	90152574
Inflammation	19.31	17.92	7	19358	178585	90430497
Injury	19.30	17.92	9	19356	197340	90411742
Multiple organ dysfunction syndrome	19.16	17.92	44	19321	68292	90540790
Parkinsonism	19.05	17.92	19	19346	14046	90595036
Incorrect product administration duration	18.95	17.92	22	19343	19300	90589782
Blister	18.92	17.92	16	19349	254982	90354100
Product use issue	18.61	17.92	26	19339	329893	90279189
Product dose omission issue	18.53	17.92	21	19344	291666	90317416
Hypotension	18.52	17.92	126	19239	325271	90283811
Right atrial enlargement	18.23	17.92	5	19360	222	90608860
Eczema	18.21	17.92	37	19328	52833	90556249

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	259.63	17.37	77	21974	1830	42597454
Migraine	250.96	17.37	159	21892	25255	42574029
Tinnitus	244.05	17.37	164	21887	28774	42570510
Palmoplantar keratoderma	238.57	17.37	75	21976	2179	42597105
Tension headache	230.78	17.37	81	21970	3333	42595951
Pruritus genital	226.95	17.37	75	21976	2564	42596720
Sleep terror	219.35	17.37	75	21976	2851	42596433
Atrial tachycardia	201.09	17.37	77	21974	4063	42595221
Carotid artery occlusion	200.12	17.37	77	21974	4117	42595167
Facial pain	198.95	17.37	77	21974	4183	42595101
Palpitations	195.09	17.37	181	21870	50616	42548668
Anosmia	184.43	17.37	77	21974	5099	42594185
Burns second degree	181.96	17.37	80	21971	6016	42593268
Catarrh	180.11	17.37	79	21972	5907	42593377
Gingival pain	177.29	17.37	87	21964	8407	42590877
Immunisation	172.14	17.37	51	22000	1207	42598077
Lip swelling	170.29	17.37	112	21939	18941	42580343
Steroid dependence	165.10	17.37	77	21974	6645	42592639
Hypopnoea	162.32	17.37	80	21971	7802	42591482
Parosmia	161.19	17.37	79	21972	7612	42591672
Pain of skin	157.49	17.37	79	21972	8001	42591283
Systemic lupus erythematosus	149.63	17.37	80	21971	9244	42590040
Angioedema	149.01	17.37	144	21907	42333	42556951
Swollen tongue	134.25	17.37	101	21950	21130	42578154
Cardiac murmur	133.76	17.37	83	21968	12692	42586592
Rhinitis	133.53	17.37	81	21970	11896	42587388
Eye pruritus	131.93	17.37	79	21972	11333	42587951
Pericarditis	127.39	17.37	82	21969	13362	42585922
Muscle twitching	124.51	17.37	77	21974	11703	42587581
Abdominal discomfort	124.36	17.37	173	21878	75082	42524202
Subarachnoid haemorrhage	124.28	17.37	83	21968	14389	42584895
Tubulointerstitial nephritis	118.32	17.37	111	21940	31437	42567847
Rash papular	114.28	17.37	73	21978	11738	42587546
Bronchiectasis	112.32	17.37	85	21966	17934	42581350
Impaired work ability	110.26	17.37	72	21979	12019	42587265
Vasculitis	106.40	17.37	83	21968	18311	42580973
Alcohol poisoning	104.98	17.37	59	21992	7515	42591769
Death	101.85	17.37	59	21992	471126	42128158
Blindness	101.57	17.37	80	21971	17898	42581386
Nightmare	101.53	17.37	92	21959	24920	42574364
Accidental overdose	95.49	17.37	94	21957	28236	42571048
Colitis ulcerative	94.14	17.37	90	21961	26085	42573199
Frequent bowel movements	91.35	17.37	81	21970	21326	42577958
Adverse drug reaction	90.33	17.37	104	21947	37330	42561954
Diplopia	88.95	17.37	78	21973	20238	42579046
Intentional product use issue	83.09	17.37	140	21911	71693	42527591
Impaired quality of life	82.05	17.37	64	21987	14113	42585171
Transient ischaemic attack	81.85	17.37	94	21957	33645	42565639
Vertigo	80.49	17.37	94	21957	34253	42565031
Rectal haemorrhage	80.34	17.37	113	21938	49493	42549791
Medication error	79.81	17.37	92	21959	33062	42566222
Alopecia	76.87	17.37	85	21966	29191	42570093
COVID-19	70.51	17.37	173	21878	115775	42483509
Amnesia	70.28	17.37	80	21971	28357	42570927
Ventricular tachycardia	69.76	17.37	82	21969	30078	42569206
Visual impairment	69.49	17.37	98	21953	43015	42556269
Dysgeusia	69.39	17.37	87	21964	34102	42565182
Dry skin	69.37	17.37	104	21947	48234	42551050
Disturbance in attention	68.74	17.37	81	21970	29785	42569499
Eczema	64.85	17.37	84	21967	34002	42565282
Cognitive disorder	61.59	17.37	82	21969	34090	42565194
Dizziness	59.67	17.37	271	21780	248983	42350301
Drug ineffective	56.46	17.37	155	21896	630042	41969242
Haematochezia	56.09	17.37	105	21946	58331	42540953
Arthritis	55.42	17.37	87	21964	41978	42557306
Muscular weakness	54.40	17.37	128	21923	83370	42515914
Febrile neutropenia	53.37	17.37	15	22036	185688	42413596
Hallucination	52.31	17.37	101	21950	57406	42541878
Myocardial infarction	50.58	17.37	160	21891	123849	42475435
Blood glucose increased	46.93	17.37	112	21939	73587	42525697
Stress	46.93	17.37	83	21968	44129	42555155
Memory impairment	46.65	17.37	89	21962	50133	42549151
Feeling abnormal	44.38	17.37	106	21945	69680	42529604
Pain	44.27	17.37	246	21805	244602	42354682
Heart rate increased	44.18	17.37	90	21961	53165	42546119
Chest pain	43.78	17.37	165	21886	139365	42459919
Peripheral swelling	41.98	17.37	122	21929	90148	42509136
Product dose omission issue	41.59	17.37	14	22037	154351	42444933
Cerebrovascular accident	41.11	17.37	127	21924	97033	42502251
Loss of personal independence in daily activities	41.09	17.37	84	21967	49732	42549552
Nail bed bleeding	39.30	17.37	13	22038	445	42598839
Confusional state	38.38	17.37	180	21871	167417	42431867
Pneumonia	35.34	17.37	107	21944	422042	42177242
Hyperhidrosis	33.47	17.37	113	21938	90399	42508885
Completed suicide	33.45	17.37	5	22046	96460	42502824
Disease progression	30.87	17.37	18	22033	143638	42455646
Abdominal pain upper	30.42	17.37	103	21948	82506	42516778
Off label use	29.83	17.37	201	21850	638134	41961150
Headache	27.08	17.37	214	21837	239155	42360129
Neutropenia	26.33	17.37	39	22012	199392	42399892
Deep vein thrombosis	24.93	17.37	92	21959	76865	42522419
Thrombocytopenia	24.36	17.37	38	22013	190241	42409043
Intentional product misuse	23.51	17.37	78	21973	61822	42537462
Septic shock	23.50	17.37	9	22042	91663	42507621
Leukopenia	23.47	17.37	5	22046	74741	42524543
Pain in extremity	23.08	17.37	145	21906	150459	42448825
Toxicity to various agents	22.98	17.37	53	21998	229083	42370201
Sepsis	22.60	17.37	43	22008	199291	42399993
Malignant neoplasm progression	21.34	17.37	15	22036	108385	42490899
Hospitalisation	21.33	17.37	6	22045	74324	42524960
Interstitial lung disease	21.32	17.37	7	22044	78455	42520829
Drug abuse	21.29	17.37	14	22037	104757	42494527
Tachycardia	20.55	17.37	105	21946	100982	42498302
Dehydration	20.19	17.37	134	21917	141633	42457651
Injection site pain	20.02	17.37	3	22048	57795	42541489
Daydreaming	20.00	17.37	9	22042	714	42598570
Insomnia	19.46	17.37	116	21935	118137	42481147
Scrotal oedema	19.02	17.37	12	22039	1887	42597397
Product use issue	18.91	17.37	8	22043	76743	42522541
Thrombosis	18.81	17.37	6	22045	68505	42530779
Syncope	18.65	17.37	101	21950	99305	42499979
International normalised ratio increased	18.56	17.37	61	21990	48107	42551177
Liver function test abnormal	18.25	17.37	47	22004	32344	42566940
Treatment failure	18.07	17.37	5	22046	62619	42536665
Orthostatic hypotension	17.89	17.37	45	22006	30525	42568759
Sleep inertia	17.61	17.37	4	22047	31	42599253
Pancytopenia	17.59	17.37	21	22030	117722	42481562
Depression	17.53	17.37	108	21943	111255	42488029

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	585.25	16.48	164	38191	4803	110546141
Palmoplantar keratoderma	563.14	16.48	162	38193	5225	110545719
Pruritus genital	532.55	16.48	162	38193	6360	110544584
Sleep terror	517.66	16.48	159	38196	6451	110544493
Tension headache	490.21	16.48	167	38188	9451	110541493
Carotid artery occlusion	487.19	16.48	166	38189	9399	110541545
Atrial tachycardia	474.20	16.48	161	38194	9017	110541927
Tinnitus	462.01	16.48	278	38077	60262	110490682
Anosmia	429.58	16.48	162	38193	12310	110538634
Facial pain	390.23	16.48	160	38195	15179	110535765
Immunisation	383.66	16.48	107	38248	3076	110547868
Pain of skin	368.12	16.48	166	38189	19863	110531081
Muscle twitching	350	16.48	182	38173	29753	110521191
Lip swelling	341.51	16.48	215	38140	50452	110500492
Vasculitis	335.34	16.48	188	38167	35685	110515259
Subarachnoid haemorrhage	322.86	16.48	172	38183	29530	110521414
Angioedema	302.52	16.48	260	38095	98240	110452704
Eye pruritus	296.15	16.48	168	38187	32607	110518337
Palpitations	277.45	16.48	308	38047	158904	110392040
Blindness	272.20	16.48	165	38190	36194	110514750
Catarrh	255.20	16.48	96	38259	7239	110543705
Burns second degree	253.85	16.48	97	38258	7636	110543308
Diplopia	245.88	16.48	163	38192	41731	110509213
Ventricular tachycardia	244.87	16.48	174	38181	49835	110501109
Hypopnoea	240.31	16.48	104	38251	11276	110539668
Transient ischaemic attack	238.41	16.48	189	38166	63793	110487151
Steroid dependence	234.83	16.48	94	38261	8375	110542569
Hallucination	233.77	16.48	228	38127	101204	110449740
Rash papular	218.72	16.48	130	38225	27509	110523435
Disturbance in attention	215.83	16.48	176	38179	61819	110489125
Gingival pain	208.11	16.48	104	38251	15632	110535312
Migraine	205.96	16.48	275	38080	171377	110379567
Parosmia	200.96	16.48	96	38259	13084	110537860
Cardiac murmur	167.11	16.48	105	38250	24523	110526421
Nightmare	162.60	16.48	123	38232	38740	110512204
Swollen tongue	160.65	16.48	147	38208	60215	110490729
Tubulointerstitial nephritis	155.90	16.48	138	38217	54146	110496798
Myocardial infarction	155.71	16.48	256	38099	191827	110359117
Accidental overdose	155.34	16.48	135	38220	51699	110499245
Rhinitis	155.18	16.48	97	38258	22448	110528496
Dry skin	155.15	16.48	189	38166	107464	110443480
Cognitive disorder	151.79	16.48	169	38186	87342	110463602
COVID-19	147.78	16.48	287	38068	244773	110306171
Blood glucose increased	140.40	16.48	200	38155	132296	110418648
Amnesia	132.71	16.48	173	38182	105235	110445709
Visual impairment	130.94	16.48	195	38160	134233	110416711
Bronchiectasis	125.71	16.48	103	38252	36390	110514554
Alcohol poisoning	123.36	16.48	61	38294	8959	110541985
Impaired work ability	118.06	16.48	87	38268	26332	110524612
Medication error	114.49	16.48	161	38194	105205	110445739
Heart rate increased	114.23	16.48	190	38165	143644	110407300
Rectal haemorrhage	111.25	16.48	170	38185	119663	110431281
Dehydration	111.19	16.48	277	38078	279234	110271710
Hyperhidrosis	109.99	16.48	217	38138	187081	110363863
Dizziness	104.09	16.48	498	37857	697695	109853249
Drug ineffective	101.11	16.48	238	38117	1520302	109030642
Intentional product misuse	100.79	16.48	172	38183	132732	110418212
Impaired quality of life	97.72	16.48	82	38273	29935	110521009
Feeling abnormal	96.16	16.48	201	38154	180510	110370434
Colitis ulcerative	95.85	16.48	126	38229	77237	110473707
Adverse drug reaction	92.73	16.48	146	38209	105413	110445531
Infusion related reaction	91.59	16.48	12	38343	381150	110169794
Frequent bowel movements	89.57	16.48	117	38238	71273	110479671
Tachycardia	89.46	16.48	224	38131	226421	110324523
Eczema	86.87	16.48	116	38239	72177	110478767
Drug intolerance	82.12	16.48	20	38335	406492	110144452
Dysgeusia	80.59	16.48	110	38245	69875	110481069
Muscular weakness	80.28	16.48	228	38127	248240	110302704
Vertigo	73.32	16.48	118	38237	86752	110464192
Death	70.77	16.48	83	38272	698786	109852158
Hyponatraemia	70.56	16.48	200	38155	217453	110333491
Intentional product use issue	70.10	16.48	217	38138	247689	110303255
Maternal exposure during pregnancy	69.13	16.48	5	38350	254878	110296066
Abdominal discomfort	69.06	16.48	295	38060	393563	110157381
Memory impairment	68.81	16.48	186	38169	196758	110354186
Chest pain	67.61	16.48	284	38071	376091	110174853
Arthropathy	64.57	16.48	11	38344	287511	110263433
Hepatic enzyme increased	64.38	16.48	16	38339	320876	110230068
Cerebrovascular accident	64.13	16.48	172	38183	181112	110369832
Therapeutic product effect incomplete	61.83	16.48	4	38351	223801	110327143
Contraindicated product administered	61.62	16.48	7	38348	248260	110302684
Haematochezia	58.53	16.48	126	38229	115398	110435546
Febrile neutropenia	57.63	16.48	19	38336	316748	110234196
Treatment failure	57.23	16.48	13	38342	277221	110273723
Blood creatine increased	56.16	16.48	40	38315	11481	110539463
Confusional state	55.59	16.48	314	38041	468366	110082578
Bradycardia	55.44	16.48	148	38207	155369	110395575
Impaired healing	52.93	16.48	4	38351	196713	110354231
Drug hypersensitivity	51.43	16.48	49	38306	454041	110096903
Product dose omission issue	50.82	16.48	24	38331	321758	110229186
Sinusitis	50.23	16.48	20	38335	296668	110254276
Infection	49.97	16.48	32	38323	362168	110188776
Swelling	49.84	16.48	30	38325	351011	110199933
Back pain	46.94	16.48	253	38102	370743	110180201
Nasopharyngitis	46.50	16.48	41	38314	394320	110156624
Helicobacter infection	45.45	16.48	5	38350	181872	110369072
Pericarditis	45.43	16.48	173	38182	218941	110332003
Therapeutic product effect decreased	43.83	16.48	15	38340	244301	110306643
Hyperkalaemia	43.22	16.48	124	38231	135672	110415272
Stomatitis	42.90	16.48	20	38335	270222	110280722
Wound	42.74	16.48	14	38341	234423	110316521
Stress	42.44	16.48	105	38250	105243	110445701
Fibromyalgia	41.95	16.48	5	38350	170904	110380040
Injection site pain	41.76	16.48	6	38349	177916	110373028
Blood cholesterol increased	41.63	16.48	7	38348	184778	110366166
Exposure during pregnancy	40.84	16.48	5	38350	167419	110383525
Syncope	39.61	16.48	157	38198	202379	110348565
Anxiety	39.43	16.48	229	38126	344849	110206095
Weight increased	39.12	16.48	53	38302	419591	110131353
Asthma	37.51	16.48	20	38335	250271	110300673
Deep vein thrombosis	37.25	16.48	120	38235	139767	110411177
Discomfort	37.12	16.48	14	38341	214693	110336251
Nail bed bleeding	36.43	16.48	13	38342	843	110550101
Ill-defined disorder	35.20	16.48	6	38349	156847	110394097
Product use issue	34.85	16.48	34	38321	311661	110239283
Scrotal oedema	34.30	16.48	15	38340	1666	110549278
Off label use	32.73	16.48	348	38007	1499837	109051107
Liver function test abnormal	32.41	16.48	73	38282	68877	110482067
Hypersensitivity	31.94	16.48	57	38298	403941	110147003
Bursitis	31.39	16.48	4	38351	129914	110421030
Joint range of motion decreased	31.34	16.48	3	38352	121829	110429115
Musculoskeletal stiffness	30.73	16.48	31	38324	279791	110271153
Gingival hypertrophy	30.72	16.48	19	38336	4312	110546632
Insomnia	30.58	16.48	222	38133	360368	110190576
Blister	30.12	16.48	21	38334	227355	110323589
Type 2 diabetes mellitus	29.90	16.48	12	38343	177220	110373724
Neutropenia	29.48	16.48	53	38302	374567	110176377
Peripheral swelling	29.40	16.48	240	38115	403794	110147150
Disease progression	29.20	16.48	25	38330	244009	110306935
Psoriatic arthropathy	29.07	16.48	16	38339	196745	110354199
Pulmonary embolism	28.97	16.48	149	38206	214325	110336619
Alopecia	28.91	16.48	221	38134	364532	110186412
Completed suicide	28.79	16.48	25	38330	242356	110308588
Rheumatoid arthritis	28.76	16.48	37	38318	299576	110251368
Abdominal pain upper	28.50	16.48	213	38142	348898	110202046
Musculoskeletal pain	28.35	16.48	14	38341	183009	110367935
Hospitalisation	26.88	16.48	8	38347	142485	110408459
Spider naevus	26.83	16.48	7	38348	155	110550789
Dyspnoea	25.44	16.48	531	37824	1106341	109444603
General physical health deterioration	25.41	16.48	70	38285	425225	110125719
Injury	25.35	16.48	15	38340	177250	110373694
Pneumonia	24.90	16.48	190	38165	876524	109674420
Adverse event	24.78	16.48	4	38351	108805	110442139
Neuropathy peripheral	24.49	16.48	16	38339	179261	110371683
Septic shock	24.47	16.48	12	38343	157516	110393428
Road traffic accident	24.34	16.48	4	38351	107394	110443550
Thrombocytopenia	24.31	16.48	53	38302	348832	110202112
Gastrointestinal disorder	24.14	16.48	29	38326	241923	110309021
Liver disorder	23.39	16.48	10	38345	142233	110408711
Wound infection	23.23	16.48	3	38352	96462	110454482
Mucosal inflammation	23.13	16.48	3	38352	96138	110454806
Hypertension	22.93	16.48	95	38260	509989	110040955
Drug ineffective for unapproved indication	22.93	16.48	4	38351	102834	110448110
International normalised ratio increased	22.70	16.48	74	38281	86698	110464246
Orthostatic hypotension	22.54	16.48	62	38293	66187	110484757
Therapeutic response decreased	20.98	16.48	4	38351	96495	110454449
Malignant neoplasm progression	20.73	16.48	18	38337	174549	110376395
Malaise	20.51	16.48	337	38018	671482	109879462
Lethargy	20.30	16.48	75	38280	93501	110457443
Pyrexia	20.30	16.48	430	37925	897835	109653109
Somnolence	20.19	16.48	174	38181	297275	110253669
Pruritus	20.14	16.48	298	38057	581262	109969682
Dyspepsia	20.01	16.48	22	38333	190943	110360001
Loss of personal independence in daily activities	19.40	16.48	103	38252	149917	110401027
Contusion	19.27	16.48	32	38323	233329	110317615
Daydreaming	19.07	16.48	9	38346	1193	110549751
Illness	18.75	16.48	3	38352	82168	110468776
Injection site erythema	18.29	16.48	5	38350	94171	110456773
Sleep inertia	18.20	16.48	4	38351	41	110550903
Penile oedema	18.02	16.48	6	38349	316	110550628
Sciatica	17.77	16.48	5	38350	92394	110458550
Polyuria	17.63	16.48	26	38329	17712	110533232
Sleep disorder	17.58	16.48	26	38329	198618	110352326
Skin oedema	17.38	16.48	10	38345	1989	110548955
Hypercholesterolaemia	17.31	16.48	5	38350	90832	110460112
Thrombosis	17.30	16.48	8	38347	108654	110442290
Faeces discoloured	17.15	16.48	37	38318	33911	110517033
Nodal rhythm	16.95	16.48	12	38343	3411	110547533
Therapy non-responder	16.62	16.48	18	38337	157289	110393655
Lung disorder	16.49	16.48	23	38332	180024	110370920

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07FB02	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers
ATC	C08CA02	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
ATC	C09BB05	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
FDA CS	M0006414	Dihydropyridines
FDA MoA	N0000000069	Calcium Channel Antagonists
FDA EPC	N0000175421	Dihydropyridine Calcium Channel Blocker
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D049990	Membrane Transport Modulators
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:38215	calcium channel blocker
CHEBI has role	CHEBI:145947	antiatherosclerotic agent

Related Drugs by ATC class:

C07FB Beta blocking agents and calcium channel blockers 6 drugs

amlodipine atenolol bisoprolol metoprolol nebivolol nifedipine

C08CA Dihydropyridine derivatives 17 drugs

amlodipine barnidipine benidipine celecoxib cilnidipine clevidipine isradipine lacidipine lercanidipine levamlodipine manidipine nicardipine show all 17 →

C09BB ACE inhibitors and calcium channel blockers 13 drugs

amlodipine benazepril delapril enalapril lercanidipine lisinopril manidipine nitrendipine perindopril ramipril trandolapril verapamil show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Prinzmetal angina	off-label use	87343002
Angina pectoris	off-label use	194828000
Raynaud's phenomenon	off-label use	266261006
Hyperkalemia	contraindication	14140009
Myocardial infarction	contraindication	22298006	DOID:5844
Acute cerebrovascular insufficiency	contraindication	29322000
Immunosuppression	contraindication	38013005
Angioedema	contraindication	41291007	DOID:1558
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Aortic valve stenosis	contraindication	60573004	DOID:1712
Transplantation	contraindication	77465005
Chronic idiopathic constipation	contraindication	82934008
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Hypertrophic cardiomyopathy	contraindication	233873004	DOID:11984
Disease of liver	contraindication	235856003	DOID:409
Peripheral edema	contraindication	271809000
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Hemodialysis with High-Flux Membrane	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.68	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel	Q13936	CAC1C_HUMAN	BLOCKER			WOMBAT-PK	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1D	Ion channel	Q01668	CAC1D_HUMAN	BLOCKER			WOMBAT-PK	CHEMBL
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.30	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.52	WOMBAT-PK
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	6.22	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.34	DRUG MATRIX
Cystic fibrosis transmembrane conductance regulator	Ion channel	P13569	CFTR_HUMAN	ACTIVATOR	Ki	8.40	IUPHAR
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	4.43	CHEMBL
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		Ki	5.17	WOMBAT-PK

External reference:

ID	Source
4020159	VUID
N0000148116	NUI
D00319	KEGG_DRUG
4020159	VANDF
C0015772	UMLSCUI
CHEBI:585948	CHEBI
225	PDB_CHEM_ID
CHEMBL1480	ChEMBL_ID
DB01023	DRUGBANK_ID
D015736	MESH_DESCRIPTOR_UI
3333	PUBCHEM_CID
4190	IUPHAR_LIGAND_ID
4877	INN_ID
OL961R6O2C	UNII
4316	RXNORM
4716	MMSL
62563	MMSL
d00231	MMSL
003602	NDDF
108535009	SNOMEDCT_US
386863007	SNOMEDCT_US
OL961R6O2C	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-3581	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	22 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-3582	TABLET, EXTENDED RELEASE	5 mg	ORAL	ANDA	22 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-3583	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	22 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	13668-132	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	17 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	13668-133	TABLET, EXTENDED RELEASE	5 mg	ORAL	ANDA	17 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	13668-134	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-048	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	10 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-048	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	10 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-049	TABLET, EXTENDED RELEASE	5 mg	ORAL	ANDA	10 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-049	TABLET, EXTENDED RELEASE	5 mg	ORAL	ANDA	10 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-050	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	10 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-050	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	10 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1124	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2421	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4808	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	19 sections
Felodipine	Human Prescription Drug Label	1	50090-5870	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	19 sections
Felopdipine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7206	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-087	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	21 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-088	TABLET, FILM COATED	5 mg	ORAL	ANDA	21 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-089	TABLET, FILM COATED	10 mg	ORAL	ANDA	21 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0823	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	24 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0826	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5197	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	24 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-411	TABLET, FILM COATED, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	11 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-412	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	11 sections
FELODIPINE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-414	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	11 sections
Felodipine	Human Prescription Drug Label	1	57237-108	TABLET, FILM COATED, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	19 sections
Felodipine	Human Prescription Drug Label	1	57237-109	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	19 sections
Felodipine	Human Prescription Drug Label	1	57237-110	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	19 sections
Felodipine	HUMAN PRESCRIPTION DRUG LABEL	1	61442-431	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	21 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

felodipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: